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Abstract
Exocrine pancreatic insufficiency (EPI) resulting from conditions such as chronic pancreatitis (CP), acute
pancreatitis (AP) and upper gastrointestinal (GI) surgery increases risk for malnutrition and metabolic
problems. Poor nutrition is associated with more complications and higher mortality. Therefore, effective
nutritional management should be a high priority in these patients. In CP, poor nutrition has been shown
to significantly affect quality of life and functional status. Clinical study data show that dietary counselling
combined with pancreatic enzyme replacement therapy is effective in improving nutritional status and
is therefore recommended in these patients. In AP, early enteral nutrition reduces complications and
mortality. However, EPI persists in many cases after the resolution of AP; these patients remain at
increased risk for malnutrition and require further nutritional support. In patients undergoing surgery,
preoperative weight loss is a risk factor for postoperative morbidity and mortality; outcomes can be
improved considerably by preoperative screening to identify high-risk patients and by providing appro-
priate perioperative nutritional support. Pre- and perioperative enteral nutrition are cost-effective inter-
ventions that can improve outcomes in patients undergoing GI surgery. In all of these patient populations,
nutritional management, including risk assessment and individualized nutritional support, is a key com-
ponent of an effective multimodal therapeutic approach.
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Introduction
Malnutrition describes a metabolic state that reduces the capacity
of an organism to cope with an insult or stress, such as major
surgery. Malnutrition may be static as, for example, in disorders
associated with very low body weight such as marasmus and
kwashiorkor, or dynamic, such as in anorexia or weight loss or
gain as a result of another acute or chronic illness. A focus on
only actual body weight or body mass index (BMI) often leads
to an underestimation of the latter in the clinical setting.
For example, if a patient with slight obesity and a BMI of
30–35 kg/m2 loses 10–15% of his body weight in a short period
of time, he is clearly malnourished but still has a BMI within the
normal range of 20–25 kg/m2, which may confound the diagnosis
of malnutrition.
Exocrine pancreatic insufficiency (EPI) presents in many dif-
ferent clinical settings, such as chronic pancreatitis (CP), cystic
fibrosis, pancreatic cancer, acute pancreatitis (AP), severe critical
illness and after major upper gastrointestinal (GI) surgery (e.g.
gastrectomy and pancreatic resection). The specific situation of
patients with EPI resulting from cystic fibrosis will not be dis-
cussed in this article. EPI is characterized by inadequate intralu-
minal pancreatic enzyme activity, resulting in maldigestion of
mainly lipids and to a lesser extent of proteins and carbohydrates,
which may result in a negative energy balance and malnutrition.
The risk for weight loss, malnutrition and deficiency of specific
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nutrients increases with the severity of EPI. In these patients,
available energy is reduced not only by maldigestion, but also by
lower food intake caused by symptoms such as pain or postopera-
tive nausea, and risk factors such as alcohol in CP or additional
socioeconomic factors. In addition, energy expenditure increases
as a result of the underlying disease and associated complications
such as diabetes mellitus and chronic inflammation. Together,
these factors lead to a negative energy balance and increased risk
for micro- and macronutrient deficiency, weight loss, and the
development of undernutrition and malnutrition.
Nutrition issues in patients with EPI should be a high priority
in the clinical setting but are rarely the focus of attention in the
management of such patients. Results from the EuroOOPS pro-
spective cohort study highlight the importance of effective nutri-
tional management in hospitalized patients.1 The aim of this study
was to implement nutritional risk screening (NRS-2002) in hos-
pitalized patients and to assess the association between nutritional
risk and clinical outcome. A total of 5051 patients were screened in
26 European hospitals and data were collected on complications,
mortality and length of hospital stay. Overall, 32.6% of patients
were defined as ‘at-risk’ by NRS-2002. This patient group had
more complications (30.6% vs. 11.3%), higher mortality (12% vs.
1%) and longer hospital stay (9 days vs. 6 days) compared with
‘not at-risk’ patients (Fig. 1).1
Malnutrition in chronic pancreatitis
It is widely acknowledged that patients with CP are often under-
nourished, but there have been few well-conducted clinical studies
assessing this. In a study conducted in a medical rehabilitation
clinic setting (cognitive treatment) assessing 155 patients with CP
(74% alcoholic pancreatitis), low BMI and ongoing maldigestion
were prevalent: 32% of patients had a BMI of <20 kg/m2; 57% had
continued diarrhoea, and 24% had steatorrhoea of >30 g/day.2 In
a further study evaluating patients with CP scheduled for elective
surgery (n = 224), the median preoperative BMI was 22 kg/m2
(23% of patients had a BMI of <20 kg/m2). Following surgery,
the median weight gain was only 2 kg (range -31 kg to +37 kg).
These results suggest that many patients are malnourished
prior to surgery and that the problem remains after surgery in a
substantial proportion of patients with CP.3
Body weight can be divided into lean body mass (functional
capacity) and fat mass (energy store). Haaber and colleagues
investigated body composition in 32 patients with CP and residual
pancreatic function (no enzyme supplementation) and in 26
patients with CP and severe EPI and steatorrhoea (receiving
enzyme supplementation).4 Both groups showed a decrease in
lean body mass, suggesting reduced functional capacity. Fat mass
was also reduced in both groups, but to a significantly greater
extent in patients with severe EPI compared with patients with
residual pancreatic function.
What do these findings mean in terms of patient quality of life
and functional capacity? A study investigating quality of life in
patients with CP (n = 66) indicated that poor nutritional status
negatively affects quality of life; using the European Organisation
for Research and Treatment of Cancer (EORTC) quality of life
questionnaire for pancreatic cancer, this study found that 34%
of patients had moderate to severe weight loss, which affected
their quality of life.5 The study also found that fatigue had a major
impact on quality of life in these patients, with 46% reporting
moderate to severe fatigue. These findings raise questions about
what we can do to improve quality of life in our patients. In
a randomized controlled trial (RCT) comparing dietary counsel-
ling (n = 29) with commercial dietary supplementation (n = 31)
in undernourished patients with CP (BMI of <18.5 kg/m2 or
loss of >10% of body weight in the previous 6 months) receiv-
ing pancreatic enzyme replacement therapy (PERT), BMI and
body weight increased and faecal fat decreased to a similar extent
in both groups (Fig. 2).6 Energy intake also increased in both
study groups. These data clearly show that adequate nutritional
management together with PERT has the potential to improve
nutritional status and maldigestion. It should be noted that
impairment of digestive capacity persists in patients with EPI
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Figure 1 Association between nutritional risk (according to Nutri-
tional Risk Screening [NRS] 2002) and clinical outcome in hospital-
ized patients. A prospective survey in 26 European hospitals
(n = 5051)1
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Figure 2 Effect of dietary counselling (n = 29) or commercial dietary
supplementation (n = 31) for 3 months on body mass index (BMI),
body weight and faecal fat in undernourished patients with chronic
pancreatitis receiving pancreatic enzyme replacement therapy.
*P = 0.007 and †P = 0.001 vs. baseline6
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even with clinically adequate PERT.7 Dietary counselling together
with PERT should be recommended initially for CP patients
with EPI. The principals of PERT are described elsewhere in this
supplement.8
Nutritional support in acute pancreatitis
In patients suffering an attack of AP, enteral nutrition has been
shown to be highly beneficial in reducing morbidity and multi-
organ failure.9 Early enteral nutrition (within 24 h of admission to
hospital) is recommended in patients with AP as it has been
shown to reduce complications, length of hospital stay and mor-
tality,9 thereby improving the disease course. A small number of
studies have shown that patients who undergo surgical procedures
for AP also benefit from early postoperative enteral nutrition in
terms of reduced morbidity and mortality rates compared with
conventional support or total parenteral nutrition.10–12
The problem of EPI should also be considered in the AP patient
population. Experimental data from animal studies carried out 20
years ago showed that exocrine pancreatic secretion is impaired in
AP.13 Several clinical studies have established that EPI is present
during and after severe AP attacks,14–16 although the clinical rel-
evance of this is not yet clear and RCTs are needed to assess this
further. A recently published study confirmed that EPI not only
occurs during AP, but persists once the attack has resolved.17 Of 86
patients initially surviving transluminal endoscopic removal of
(peri) pancreatic necroses after an attack of severe AP (with or
without further surgery), more than one-third (36%) were still
taking PERT at a mean follow-up of 44 months (range 4–96
months). Longterm follow-up of 79 patients (median 50 months,
range 15–96 months) indicated that 13% had significant weight
loss and more than half (58%) had to change their diets owing
to digestive problems. These data highlight the fact that many
patients with EPI after severe AP still have an increased risk for
malnutrition. Further evaluation of PERT and nutritional man-
agement is therefore essential after the resolution of AP in this
patient population.
Nutrition following upper
gastrointestinal surgery
At the time of diagnosis, patients with GI carcinomas, particularly
of the upper GI tract, frequently have existing nutritional pro-
blems in the form of weight loss and increased prevalence of
malnutrition, as determined by the NRS-2002. Surgery for their
underlying condition is likely to increase their nutritional prob-
lems.18 It is essential that nutrition is effectively managed before,
during and after surgery, as highlighted by an analysis of data from
the National Veteran’s Affairs Surgical Quality Improvement
Program database, which includes records of 417 944 major sur-
gical procedures performed between 1991 and 1997.19 Preopera-
tive decreases in serum albumin and weight loss (>10% in 6
months), among others, were found to be independent risk factors
for postoperative morbidity and mortality in patients undergoing
non-cardiac surgery.
A meta-analysis of 27 randomized trials in patients undergoing
surgery indicated that perioperative total parenteral nutrition may
decrease the complication rate, especially in those with already
established malnutrition (relative risk 0.52, 95% confidence inter-
val 0.30–0.91), although individual study results appeared to
be influenced by method quality and year of publication.20 No
influence on mortality rate was observed in this analysis. Recent
guidelines from the European Society of Enteral and Parenteral
Nutrition (ESPEN) clearly recommend using enteral nutrition
wherever possible.21,22 A prospective study by Gianotti et al. indi-
cated that the timing of nutritional support has a major impact on
outcome, with preoperative support being crucial.23 In this study
of 305 patients with preoperative weight loss of <10% and cancer
of the GI tract, preoperative oral dietary supplementation for 5
days before surgery was as effective as combined preoperative and
perioperative supplementation in reducing infection rate and hos-
pital stay compared with no nutritional support (Fig. 3), suggest-
ing that nutritional support does not have to be longterm to be
effective. Cost–benefit analysis of these data indicated preopera-
tive nutritional supplementation can improve cost-effectiveness
by reducing postoperative complication rates: cost-effectiveness
values for preoperative and conventional support were €2985 and
€6245, respectively.24
In summary, nutrition needs to be managed effectively at all
three stages of surgery in patients with EPI, including preope-
ratively (e.g. in anorexia or weight loss), perioperatively (e.g. in
patients with an inflammatory response or metabolic risk) and
postoperatively (e.g. in convalescence or functional improvement).
Patient care can be improved considerably by preoperative screen-
ing to identify patients with high risk for malnutrition (weight
loss of >10% in 3–6 months, BMI of <18 kg/m2, albumin <30 g/l)
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Figure 3 Comparison of preoperative oral supplementation (argin-
ine, omega-3 fatty acids and ribonucleotide) for 5 days (n = 102) with
the same preoperative therapy plus postoperative jejunal infusion
(n = 101) and no artificial nutrition before or after surgery (n = 102).
*P < 0.05 and †P < 0.01 vs. no nutrition23
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and by providing nutritional support before surgery. In the perio-
perative period, metabolic control can be increased by providing
early enteral nutrition in patients who are not able to ingest a
normal diet. Postoperatively, a significant proportion of patients
still require nutritional support, including counselling and PERT
as appropriate.
Conclusions
Patients with EPI have an increased risk for malnutrition, which in
turn increases morbidity and mortality and negatively impacts on
quality of life. Along with PERT, individually tailored nutritional
management, including counselling and oral supplements as
appropriate, can improve nutritional status, reduce morbidity and
improve functional status and quality of life in patients with CP
(Fig. 4). Exocrine pancreatic function is impaired in severe AP and
remains impaired after the resolution of the attack; patients with
AP are therefore at continued risk for malnutrition and should be
monitored appropriately. For patients undergoing upper GI tract
surgery, pre- and perioperative nutritional support – mainly by
enteral nutrition – are cost-effective interventions that improve
outcomes. Nutritional management, including nutritional risk
assessment and individualized nutritional support, is therefore a
key component of an effective multimodal therapeutic approach
in diseases associated with EPI, such as CP and AP, and in patients
undergoing GI surgery.
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